Pulse Biosciences

NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue. We believe that NPES can induce a variety of cellular responses including secretion, apoptosis and necrosis by modulating the NPES pulses, making it applicable to a wide variety of cell types and therapeutic applications. One of the more promising applications of NPES is the treatment of solid tumors, where pre-clinical data have shown that NPES provides effective local tumor control and initiates an adaptive immune response with a vaccine-like effect by inducing immunogenic apoptosis of the cells. We believe we will establish NPES as a new treatment modality across a variety of applications, including oncology, dermatology, and other minimally invasive applications where current ablation modalities do not provide the benefits of NPES.
Type
Public
HQ
Burlingame, US
Pulse Biosciences is headquartered in Burlingame, US

Pulse Biosciences Office Locations

Pulse Biosciences has an office in Burlingame
Burlingame, US (HQ)
104 849 Mitten Rd

Pulse Biosciences Data and Metrics

Pulse Biosciences Financial Metrics

$, USD

Net income (FY, 2016)

(2.8 b)

Market capitalization (23-Jun-2017)

471 m

Closing share price (23-Jun-2017)

33

Cash (31-Dec-2016)

2.1 m
Pulse Biosciences's current market capitalization is $471 m.
$, USDFY, 2016

R&D expense

1.8 b

General and administrative expense

870 m

Operating expense total

2.8 b

Interest income

34 m

Net Income

(2.8 b)
$, USDFY, 2016

Cash

2.1 m

Inventories

268 k

Current Assets

16.7 m

Goodwill

2.8 m

Total Assets

26.3 m

Accounts Payable

265 k

Current Liabilities

1 m

Additional Paid-in Capital

37.9 m

Retained Earnings

(12.6 m)

Total Equity

25.3 m

Financial Leverage

1 x
$, USDFY, 2016

Net Income

(2.8 b)

Depreciation and Amortization

167 m

Inventories

12 k

Accounts Payable

29 k

Cash From Operating Activities

(101 k)

Purchases of PP&E

(46 k)

Cash From Investing Activities

(45 k)

Cash From Financing Activities

7.2 m
Y, 2016

Financial Leverage

1 x

Pulse Biosciences Operating Metrics

Pulse Biosciences's Patent Applications was reported to be 61 in FY, 2016
FY, 2016

Patents Issued

49

Patent Applications

61

Pulse Biosciences Market Value History

Pulse Biosciences Company Life and Culture

You may also be interested in